Top AI Companies in Brain Disease Detection- From stroke and brain haemorrhage to aneurysms, traumatic brain injury and early neurodegenerative changes, these AI companies are developing technologies to help clinicians detect brain diseases faster and more consistently.
The brain is one of the most complex organs to diagnose. A patient with a sudden headache, weakness, speech difficulty, confusion or loss of consciousness may need urgent brain imaging. In conditions such as stroke or intracranial haemorrhage, even a short delay in diagnosis can have serious consequences.
At the same time, not every brain disorder presents as an obvious emergency. Conditions such as dementia, Alzheimer’s disease, multiple sclerosis, brain atrophy and other neurological disorders can involve subtle structural changes that may be difficult to identify or quantify consistently through visual assessment alone.
Several companies around the world are now developing AI solutions specifically for brain and neurovascular imaging. Here are 10 AI companies in brain disease detection and neurological imaging.
1. Qure.ai – Mumbai, India
The Mumbai-based company has developed AI solutions for medical imaging, with one of its major neurological applications being qER, an AI-powered head CT solution designed to help identify critical abnormalities associated with stroke and traumatic brain injury.
qER can analyse non-contrast head CT scans and identify findings including intracranial haemorrhage, infarcts, mass effect, midline shift and cranial fractures, helping prioritise potentially critical cases for clinical review.
The company’s stroke-care platform also combines imaging AI with care coordination.
In a study conducted at Baptist Christian Hospital in Tezpur, Assam, researchers evaluated AI-assisted automated CT brain interpretation for acute stroke. The study reported a sixfold increase in the proportion of patients treated within 30 minutes and a 27% reduction in treatment time. (Qure.ai)
Qure.ai has also deployed its stroke-care technology in hub-and-spoke networks, including a collaboration involving Aster MIMS Kozhikode. Its qER system can process head CT scans and identify findings relevant to stroke triage, while its care platform helps connect teams across hospitals.
Brain conditions and applications
- Acute stroke
- Intracranial haemorrhage
- Brain infarction
- Traumatic brain injury
- Midline shift
- Mass effect
- Cranial fractures
- Large-vessel occlusion assessment
Its strongest differentiator is the combination of brain imaging AI + emergency workflow + care coordination, particularly for healthcare systems where specialist neurological expertise may not be available around the clock.
2. RapidAI – San Mateo, CA, USA
RapidAI has built a global AI platform focused heavily on stroke and neurovascular care.
Its technology analyses brain imaging from modalities including non-contrast CT, CT angiography, CT perfusion and MRI.
Its solutions can support identification of large-vessel occlusion, intracranial haemorrhage and ischemic changes while also providing automated scoring and quantitative information to help clinicians assess patients.
RapidAI’s platform includes tools such as Rapid NCCT Stroke, Rapid ASPECTS, Rapid CTA and Rapid Perfusion Imaging.
The company also offers AI-based aneurysm detection and neurocritical-care solutions, expanding its focus beyond acute ischemic stroke.
Brain conditions and applications
- Ischemic stroke
- Large-vessel occlusion
- Intracranial haemorrhage
- Cerebral ischemia
- Brain aneurysm
- Neurovascular emergencies
RapidAI’s strength is its end-to-end neurovascular imaging approach, helping clinicians move from brain imaging to treatment decisions in time-sensitive stroke pathways.
3. Brainomix – Oxford, UK
UK-based Brainomix has developed one of the more comprehensive AI platforms for stroke imaging.
Its Brainomix 360 Stroke platform analyses brain scans across multiple imaging modalities, including NCCT, CTA, CT perfusion and MRI.
The platform can identify and quantify intracranial haemorrhage, suspected large-vessel occlusion and ischemic changes, while also generating automated ASPECTS scores and other quantitative measures.
Brainomix reports that its stroke technology has been validated in more than 60 peer-reviewed studies involving over 450,000 patients.
Its platform is used across hospitals and stroke networks in more than 30 countries, according to the company.
Brain conditions and applications
- Acute ischemic stroke
- Intracranial haemorrhage
- Large-vessel occlusion
- Brain ischemia
- Stroke severity assessment
- Treatment eligibility assessment
Rather than focusing on one imaging algorithm, Brainomix is building a multimodal brain-imaging ecosystem designed around the complete stroke pathway.
4. Viz.ai – USA, UK, Netherlands
Viz.ai is a clinical AI company whose roots are strongly connected to stroke and neurovascular care.
Its platform uses AI to analyse medical imaging and trigger notifications and care coordination when potentially serious conditions are identified.
The company now reports more than 50 FDA-cleared AI algorithms across its broader platform, including a dedicated Viz Neuro suite for suspected neurovascular disease.
Its neurovascular solutions are designed to help detect conditions and accelerate communication between emergency departments, radiologists, neurologists, neurointerventional teams and other clinicians.
In July 2026, Viz.ai marked its 10th anniversary and reported that its platform had grown from its original stroke algorithm into a broader enterprise clinical AI platform.
Brain conditions and applications
- Stroke
- Intracranial haemorrhage
- Neurovascular disease
- Large-vessel occlusion
- Other acute neurological emergencies
Viz.ai illustrates how brain AI is moving beyond image detection toward care coordination — helping make sure that a positive finding reaches the right specialist quickly.
5. Aidoc – Israel, NYC, USA
Aidoc has developed a broad clinical AI platform covering radiology, neurovascular disease, cardiology and other areas.
Its neurovascular AI solutions can analyse CT imaging for suspected intracranial haemorrhage, vessel occlusion, brain aneurysms and other findings.
Aidoc’s Full Brain AI solution is designed to analyse relevant CT scans and flag both expected and unexpected neurological findings. Its platform includes AI algorithms for vessel occlusion, CT perfusion, brain aneurysms and intracranial haemorrhage.
The company also has a dedicated AI solution for detecting suspected brain aneurysms on CT angiography.
Brain conditions and applications
- Brain aneurysm
- Intracranial haemorrhage
- Large-vessel occlusion
- Medium-vessel occlusion
- Stroke
- Cervical spine injuries
Aidoc’s approach is interesting because it is not restricted to the finding a doctor is initially looking for.
Its AI orchestration platform can apply relevant algorithms to imaging and flag unexpected findings that might otherwise be missed during a busy clinical workflow.
6. Avicenna.AI – France
France-based Avicenna.AI develops AI software for radiology, with a substantial focus on emergency neurovascular imaging.
Its CINA family of solutions includes tools for intracranial haemorrhage, large-vessel occlusion and ASPECTS assessment.
Its CINA-ICH product analyses non-contrast head CT scans and is designed to detect multiple forms of intracranial bleeding, including intraparenchymal, intraventricular, subarachnoid, subdural and epidural haemorrhage.
The company also develops AI tools for traumatic brain injury and cervical spine fractures.
Brain conditions and applications
- Intracranial haemorrhage
- Hemorrhagic stroke
- Traumatic brain injury
- Large-vessel occlusion
- Ischemic stroke
- Cervical spine fracture
The company’s focus on emergency neurovascular imaging makes it particularly relevant to situations where rapid identification of a critical brain abnormality can influence the next clinical step.
7. Quibim – Valencia, Spain
While many brain AI companies focus on acute stroke, Quibim takes a different approach.
Its QP-Brain software uses AI to quantitatively analyse brain MRI scans, including brain structure volumes and white-matter hyperintensities.
The platform is designed to help detect and monitor subtle changes in brain anatomy, including brain atrophy and lesions.
This is particularly relevant to neurological diseases in which structural brain changes can develop gradually.
Quibim says QP-Brain has received regulatory clearances including FDA 510(k), CE marking and UKCA marking.
The company specifically identifies applications involving conditions such as Alzheimer’s disease, multiple sclerosis and different forms of dementia.
Brain conditions and applications
- Alzheimer’s disease
- Dementia
- Multiple sclerosis
- Brain atrophy
- White-matter abnormalities
- Neurodegenerative disease monitoring
It represents a different generation of neurological AI — one focused not only on emergency detection but on quantifying subtle structural changes over time.
8. AtrifiQ — IIT Bombay / Max Healthcare Innovation
Sunita Sanghi Centre of Aging and Neurodegenerative Diseases, IIT Bombay
India’s AI brain-health ecosystem is also beginning to move into neurodegenerative disease.
AtrifiQ is an emerging AI-powered platform developed through collaboration involving the Koita Centre for Digital Health at IIT Bombay and Max Healthcare, with support from the Sunita Sanghi Centre of Aging and Neurodegenerative Diseases at IIT Bombay.
The platform is being developed for early dementia detection using brain MRI.
According to IIT Bombay’s SCAN centre, the technology combines brain segmentation, brain-age prediction and normative modelling using Indian population data to support dementia risk assessment. The project is now being accelerated toward a startup venture with plans for broader deployment. (IIT Bombay Scan)
Brain conditions and applications
- Dementia
- Early neurodegenerative changes
- Brain atrophy
- Brain-age assessment
- MRI-based neurological risk assessment
Its biggest significance is that it represents an India-specific approach to neurodegenerative disease detection, using MRI and population-specific modelling rather than relying solely on conventional visual assessment.
9. Quantib / RadNet – Netherland, USA
Quantib, a RadNet company, has developed AI tools for neuroradiology and brain imaging.
Its technology is particularly relevant to brain atrophy and cognitive decline.
Quantib’s AI can quantify changes in brain structures and compare measurements longitudinally, potentially helping clinicians assess disease progression. RadNet describes applications involving dementia subtypes, brain atrophy and white-matter hyperintensity tracking.
This is an important category because neurological diseases such as dementia are often not diagnosed through a single dramatic imaging finding.
Instead, clinicians may need to understand how brain structures change over time.
Brain conditions and applications
- Dementia
- Cognitive decline
- Brain atrophy
- White-matter hyperintensities
- Neurodegenerative disease monitoring
Its emphasis is on quantitative and longitudinal brain analysis, potentially giving clinicians objective measurements to complement conventional MRI interpretation.
10. NeuroQuant / Cortechs.ai – USA
NeuroQuant, developed by Cortechs.ai, is another established name in AI-assisted brain MRI analysis.
Its technology uses automated brain volumetry to measure brain structures and compare them with reference populations.
A peer-reviewed review of AI-based brain MRI software lists NeuroQuant among commercially available automated brain-volumetry systems used in neurodegenerative disease assessment. (PubMed Central (PMC))
The concept is straightforward but potentially valuable: instead of relying only on whether a brain structure “looks smaller”, AI can provide quantitative measurements of brain regions.
Brain conditions and applications
- Alzheimer’s disease
- Dementia
- Brain atrophy
- Neurodegenerative disorders
- Longitudinal brain-volume monitoring
It helped establish the broader concept of automated quantitative brain volumetry, an approach that is becoming increasingly relevant as clinicians look for earlier and more objective indicators of neurodegenerative disease.
Also Read: Top 10 Indian AI Companies in Preventive Healthcare and Early Disease Detection
HealthViews Takeaway
The future of brain disease detection is becoming increasingly data-driven, quantitative and AI-assisted.
From Qure.ai’s stroke and head-CT technology in India to RapidAI and Brainomix’s neurovascular platforms, and from Aidoc’s brain aneurysm detection to Quibim and AtrifiQ’s work on brain MRI and neurodegenerative disease, AI is expanding into multiple areas of neurological care.
The most exciting development may be the shift from simply asking:
“Can AI find a brain abnormality?”
to asking:
“Can AI help doctors find it earlier, understand it better and act faster?”
That distinction could ultimately determine how valuable artificial intelligence becomes in brain health.
Editorial note: This article Top AI Companies in Brain Disease Detection is a curated HealthViews list based on publicly available information about AI products, clinical applications, validation, regulatory status and relevance to neurological diagnosis. The order is not a clinical ranking, and inclusion does not constitute medical endorsement.
